Erica Esrick, MD
Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Image
Erica Esrick, MD
Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
Pediatrics
Harvard Medical School
2004
Boston
MA
Internship
Pediatrics
Children's Memorial Hospital
2005
Chicago
IL
Residency
Pediatrics
Boston Combined Residency Program (BCRP)
2007
Boston
MA
Fellowship
Pediatric Hematology-Oncology
Boston Children's Hospital/Dana-Farber Cancer Institute
2010
Boston
MA
Media
Research
Gene therapy for sickle cell disease: The journey to a new treatment
Certifications
American Board of Pediatrics (Hematology-Oncology)
Publications
ß-Thalassemia minor is associated with high rates of worsening anemia in pregnancy. View Abstract
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease. View Abstract
Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling. View Abstract
Bidirectional processes linking social determinants of health and pediatric sickle cell anemia management: A qualitative study. View Abstract
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. View Abstract
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. View Abstract
Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. View Abstract
Investigational curative gene therapy approaches to sickle cell disease. View Abstract
ß-Thalassemia: evolving treatment options beyond transfusion and iron chelation. View Abstract
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. View Abstract
Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy. View Abstract
Highly efficient therapeutic gene editing of human hematopoietic stem cells. View Abstract
Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. View Abstract
Genetic therapies for sickle cell disease. View Abstract
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. View Abstract
Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. View Abstract
Howell-Jolly–like bodies in neutrophils. View Abstract
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. View Abstract
Preoperative visual acuity as a prognostic indicator for laser treatment of macular edema due to branch retinal vein occlusion. View Abstract
Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. View Abstract